1701 GMT - Bayer's filing to review a lower court's decision on a case alleging the company's Roundup product caused cancer is the next step forward in the litigation, Morgan Stanley analysts say. The German pharmaceutical company argues that the "failure-to-warn" claims, on which all glyphosate cases are based, are preempted by the Federal Insecticide, Fungicide, and Rodenticide Act's labeling rules, the analyst says. The Supreme Court could potentially decide on whether or not to take the case in the second quarter, with a potential final decision by end 2025 or in the first half of 2026, they say. Shares fall 1.3% to 19.83 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 07, 2025 13:01 ET (17:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。